Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
[HZNP]
Reports for Purchase
Showing records 1 - 20 ( 146 total )
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Positive Results With Tepezza Validate IGF-1R Blocking for the Treatment of Chronic TED
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Horizon Says Yes to Offer Made by Amgen; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
For Sale? Horizon Enters Early Talks To Be Acquired; Maintain Neutral; Price Target Removed
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Sustained Response at Month-12 for Krystexxa and Methotrexate; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D